{"contentid": 488731, "importid": NaN, "name": "Viral vector crunch as gene therapies, vaccines take off", "introduction": "A new report from industry analyst GlobalData finds that the global biotech industry is experiencing a shortage of viral vectors, an essential component of advanced therapies.", "content": "<p><span style=\"font-weight: 400;\">A new report from industry analyst GlobalData finds that the global biotech industry is experiencing a shortage of viral vectors, an essential component of advanced therapies.</span></p>\n<p><span style=\"font-weight: 400;\">Of pressing concern in the near-term, viral vectors are also an important element of the production process for certain COVID-19 vaccines, including AstraZeneca&rsquo;s (LSE: AZN) Vaxzevria and a similar type of jab from Johnson &amp; Johnson (NYSE: JNJ).</span></p>\n<p><span style=\"font-weight: 400;\">The </span><a href=\"https://u7061146.ct.sendgrid.net/ls/click?upn=4tNED-2FM8iDZJQyQ53jATURorIaK8X9SYLnzrEffc7kyfP-2FVfFnGmkNoyrnWr3AVm8-2F08K9h8LNlEHZT6yO4Y6d5gdiBRLDuFGYighosiO67OfiyESaWdNowjXaXvCBCIa4TExEkkS-2FgHksnL6wlB3eeHJ6ShVsh-2BuEQKKKT9tcRJBax-2BltMB7ap2BlJ5Fde3zGaT6sSQUdFCc0dkD-2FlQbA-3D-3DlaCX_kUSOyLKFh1DUjfbFLTjqYPSGTEyRmRgBhFgncVOnD15RsHNELV7fpp3RDaomW-2B6NNr9lRfDoJTQO15eUdXHqhimY-2Fj45z0gtb0EGX8Ak2FjoyHc27BzNfTIhNCdQvqixK-2F7JHkHHG1q9Yqmsje0bcjBKy-2B8C-2FzgB7GnU3JVWvWtYzdkCzkzG10iw0q5yuWirwYcycQb1EbGxLxtp6a9UWgtcrepR1OWi2d-2B0pUP7ZLYNKupHKwgsOHMofCB9rDGRqJgEkhheHyvYZ-2FZ-2Fitsqt89WiNZr36F8HrxOtEuVqhifXIVxgxejTZvIJCVk2zAO3tvBK8Ut30Vl-2FtgWitq9esBEC1cuwNsJvA9JuoH-2FYtI-3D\"><span style=\"font-weight: 400;\">report</span></a><span style=\"font-weight: 400;\"> reveals that viral vector production has been limited by an inadequate amount of manufacturing capacity, as well as inefficient processes and the need for complex facilities.</span></p>\n<p><span style=\"font-weight: 400;\">In total, there are more than a dozen products that use a viral vector which are currently marketed in the USA, Europe or Japan.</span></p>\n<p><span style=\"font-weight: 400;\">Associate editor Fiona Barry said researchers anticipated a further increase in the number of therapies which make use of viral vectors, as the technologies involved continue to mature.</span></p>\n<p><span style=\"font-weight: 400;\">She said: &ldquo;We anticipate that over 100 more gene therapies and gene-modified cell therapies will be approved over approximately the next six years. These therapies will all need viral vectors and will exacerbate the manufacturing shortage.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">There are currently an estimated 3,000 gene therapies, gene-modified cell therapies, and recombinant vector vaccines in the development pipeline.</span></p>\n<h2><strong>Solving the problem</strong></h2>\n<p><span style=\"font-weight: 400;\">The global pharmaceutical industry is working to scale up existing facilities and to improve the efficiency of its processes.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">In addition, leading contract development and manufacturing organizations (CDMOs) are making ever greater investments to boost viral vector production, by improving both upstream and downstream processes.</span></p>\n<p><span style=\"font-weight: 400;\">Ms Barry said: &ldquo;Regulatory changes would also ease the viral vector bottleneck. If agencies approve standardized viral platforms that could be used interchangeably by therapy developers, this would speed up development, approval, and technology transfer to CMOs.&rdquo;</span></p>", "date": "2021-05-25 13:12:00", "meta_title": NaN, "meta_keywords": "viral, therapies, vector, industry, vectors, report, vaccines, gene, global, shortage, production, manufacturing, processes, development, finds, GlobalData", "meta_description": "A new report from industry analyst GlobalData finds that the global biotech industry is experiencing a shortage of viral vectors, an essential component of adva", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-25 13:11:59", "updated": "2021-05-25 13:52:16", "access": NaN, "url": "https://www.thepharmaletter.com/article/viral-vector-crunch-as-gene-therapies-vaccines-take-off", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "biotech_production_bottles_big.png", "image2id": "biotech_production_bottles_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Vaccines", "topic_tag": "Production, Research", "geography_tag": "Global, USA", "company_tag": "AstraZeneca, GlobalData, Johnson & Johnson", "drug_tag": "COVID-19 Vaccine Janssen, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-25 13:12:00"}